HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shikuma, K. Articles by Taki, T. Search for Related Content PubMed Articles by Shikuma, K. Articles by Taki, T. Related Collections Lung - other

---

Case Reports

Treatment of Primary Melanoma of the Lung Monitored by 5-S-Cysteinyldopa Levels

Division of Thoracic Surgery, Respiratory Disease Center, The Tazuke Kofukai Medical, Research Institute Kitano Hospital, Kita-ku, Osaka, Japan

Accepted for publication August 20, 2008.

^_* Address correspondence to Dr Omasa, Division of Thoracic Surgery, Respiratory Disease Center, The Tazuke Kofukai Medical Research Institute Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan (Email: m-oomasa{at}kitano-hp.or.jp).

Malignant melanoma originating outside the skin is very rare, whereas primary malignant melanoma of the lung is extremely rare. 5-S-Cysteinyldopa (5-S-CD), a melanin metabolite, has been reported to be a prognostic marker for cutaneous malignant melanoma. This is the first report in the English language literature dealing with primary malignant melanoma of the lung using serum 5-S-Cysteinyldopa levels to monitor the effects of surgery and chemotherapy.